

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method for reducing ~~an~~ a T-cell mediated immune response in an animal by inhibiting an interaction between a dendritic cell and a T cell, comprising administering to an animal in need of reducing said immune response an antibody which binds to a protein with the amino acid sequence of SEQ ID NO: 2 (DC-SIGN) on the surface of a dendritic cell, wherein said antibody reduces one or more interactions between a dendritic cell and a T cell thereby reducing said immune response in the animal, and wherein the animal is not infected with HIV.

2. (Canceled)

3. (Original) The method of claim 1 wherein said animal is a mammal.

4. (Original) The method of claim 3 wherein said mammal is a human.

5. (Canceled)

6. (Previously presented) The method of claim 1 wherein said antibody reduces adhesion between DC-SIGN and an ICAM receptor on the surface of a T cell.

7. (Original) The method of claim 6 wherein said ICAM receptor is selected from the group consisting of ICAM-2 receptors and ICAM-3 receptors.

Claims 8 - 18. (Canceled)

19. (Previously presented) The method of claim 1 wherein said antibody is a monoclonal antibody.

Claims 20 - 22. (Canceled)

23. (Previously presented) The method of claim 1 wherein said antibody is selected from the group consisting of i) an antibody produced by hybridoma ECACC accession number 99040818 and ii) an antibody produced by hybridoma ECACC accession number 99040819.

24. (Previously Presented) The method of claim 1, wherein said animal is in need of tolerance, immunotherapy or immunosuppression.

25. (Previously Presented) The method of claim 1, wherein said animal is suffering from an autoimmune disease.

26. (Previously Presented) The method of claim 1, wherein said animal is suffering from an allergy.

27. (Previously presented) The method of claim 1, wherein the antibody is administered in combination with another compound selected from the group consisting of: immunosuppressants, immunomodulants, antibiotics, auto-antigens, allergens, anti-LF3A, Tumor Necrosis Factor (TNF), anti-viral agents, and CD4 inhibitors.